SAVA

Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.

Wall Street analysts forecast SAVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SAVA is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cassava Sciences Inc revenue for the last quarter amounts to -11.86M USD, decreased -61.27 % YoY.

Cassava Sciences Inc. EPS for the last quarter amounts to -6301000.00 USD, decreased -65.59 % YoY.

Cassava Sciences Inc (SAVA) has 30 emplpoyees as of January 10 2026.

Today SAVA has the market capitalization of 101.45M USD.